NYSE:BAX - Baxter International Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $96.41
  • Forecasted Upside: 20.50 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$80.01
▼ -1.08 (-1.33%)
1 month | 3 months | 12 months
Get New Baxter International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BAX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$96.41
▲ +20.50% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Baxter International in the last 3 months. The average price target is $96.41, with a high forecast of $105.00 and a low forecast of $84.00. The average price target represents a 20.50% upside from the last price of $80.01.
Buy
The current consensus among 18 investment analysts is to buy stock in Baxter International.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/5/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/3/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/1/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2020Raymond JamesLower Price TargetOutperform$95.00 ➝ $88.00Low
i
10/9/2020UBS GroupLower Price TargetBuy$98.00 ➝ $96.00Medium
i
10/1/2020CitigroupUpgradeNeutral ➝ Buy$94.00Medium
i
9/4/2020ArgusDowngradeBuy ➝ HoldMedium
i
8/11/2020Credit Suisse GroupReiterated RatingBuy$99.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
7/31/2020Credit Suisse GroupReiterated RatingBuy$99.00High
i
Rating by Matt Miksic at Credit Suisse Group AG
7/31/2020Raymond JamesLower Price TargetOutperform$97.00 ➝ $95.00Medium
i
7/31/2020Morgan StanleyLower Price TargetEqual Weight$95.00 ➝ $90.00Low
i
7/30/2020OppenheimerReiterated RatingBuyLow
i
Rating by Suraj Kalia at Oppenheimer Holdings Inc.
6/23/2020OppenheimerInitiated CoverageOutperform$100.00Medium
i
5/1/2020UBS GroupBoost Price TargetBuy$95.00 ➝ $103.00Low
i
5/1/2020SVB LeerinkBoost Price TargetOutperform$96.00 ➝ $105.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
5/1/2020Credit Suisse GroupBoost Price TargetOutperform$97.00 ➝ $99.00Low
i
5/1/2020KeyCorpBoost Price TargetOverweight$92.00 ➝ $98.00Low
i
4/30/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $100.00Low
i
4/28/2020JPMorgan Chase & Co.Boost Price TargetOverweight$94.00 ➝ $96.00Low
i
4/20/2020Wells Fargo & CompanyBoost Price TargetOverweight$92.00 ➝ $104.00Low
i
4/14/2020BarclaysReiterated RatingHold$84.00High
i
4/13/2020Raymond JamesBoost Price TargetOutperform$90.00 ➝ $97.00Low
i
4/2/2020Wells Fargo & CompanyReiterated RatingBuyHigh
i
3/27/2020Morgan StanleyBoost Price TargetHold$88.00 ➝ $95.00Low
i
Rating by David Lewis at Morgan Stanley
3/19/2020Stifel NicolausUpgradeHold ➝ Buy$87.00 ➝ $95.00High
i
3/18/2020Wells Fargo & CompanyLower Price Target$102.00 ➝ $95.00High
i
3/18/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$109.00 ➝ $99.00High
i
Rating by Pito Chickering at Deutsche Bank Aktiengesellschaft
3/18/2020CitigroupLower Price TargetNeutral$94.00 ➝ $89.00High
i
3/18/2020Credit Suisse GroupLower Price TargetOutperform$98.00 ➝ $96.00High
i
3/18/2020Raymond JamesLower Price TargetNeutral ➝ Outperform$95.00 ➝ $90.00High
i
3/18/2020KeyCorpUpgradeSector Weight ➝ Overweight$92.00High
i
3/17/2020SVB LeerinkReiterated RatingOutperformHigh
i
Rating by D. Antalffy at SVB Leerink LLC
3/6/2020Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $98.00Medium
i
3/4/2020CitigroupInitiated CoverageNeutral$94.00High
i
2/14/2020Wells Fargo & CompanyBoost Price TargetOverweight$100.00 ➝ $102.00Low
i
2/12/2020Goldman Sachs GroupInitiated CoverageBuy$104.00Low
i
2/6/2020CfraBoost Price TargetHold$87.00 ➝ $93.00Low
i
1/16/2020Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $100.00Low
i
Rating by Larry Biegelsen at Wells Fargo & Company
1/13/2020UBS GroupReiterated RatingBuy$102.00High
i
1/2/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightHigh
i
Rating by David Lewis at Morgan Stanley
1/2/2020CitigroupUpgradeNeutral ➝ BuyHigh
i
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$80.00 ➝ $94.00High
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$89.00 ➝ $94.00Low
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
12/17/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$90.00 ➝ $88.00Medium
i
10/21/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$109.00High
i
Rating by Pito Chickering at Deutsche Bank Aktiengesellschaft
10/8/2019JPMorgan Chase & Co.Set Price TargetBuy$94.00Low
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
9/10/2019Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Matthew O'Brien at Piper Jaffray Companies
7/26/2019Royal Bank of CanadaSet Price TargetHold$87.00Low
i
Rating by Glenn Novarro at Royal Bank of Canada
7/26/2019BarclaysSet Price TargetHold$82.00Low
i
Rating by Kristen Stewart at Barclays PLC
7/26/2019Wells Fargo & CompanySet Price TargetBuy$95.00Low
i
Rating by Larry Biegelsen at Wells Fargo & Company
7/26/2019Raymond JamesBoost Price TargetOutperform$84.00 ➝ $95.00Low
i
7/26/2019Credit Suisse GroupBoost Price TargetReduce ➝ Outperform$84.00 ➝ $95.00Low
i
7/26/2019BMO Capital MarketsBoost Price TargetOutperform$95.00Low
i
7/25/2019Piper Jaffray CompaniesBoost Price TargetOverweight$90.00 ➝ $95.00Low
i
6/26/2019Wells Fargo & CompanyBoost Price TargetOutperform$89.00 ➝ $91.00Low
i
6/25/2019KeyCorpInitiated CoverageSector Weight ➝ Sector WeightMedium
i
6/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$80.00 ➝ $90.00Low
i
5/13/2019JPMorgan Chase & Co.Boost Price TargetOverweight$80.00 ➝ $88.00Low
i
4/22/2019CowenSet Price TargetHold$75.00Low
i
Rating by Josh Jennings at Cowen Inc
4/15/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$72.00 ➝ $75.00Low
i
Rating by Kristen Stewart at Barclays PLC
4/3/2019Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$80.00 ➝ $89.00Medium
i
3/5/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $83.00Low
i
2/1/2019BarclaysUpgradeUnderweight ➝ Equal Weight$67.00 ➝ $72.00Low
i
2/1/2019Piper Jaffray CompaniesReiterated RatingOverweight$80.00Low
i
1/2/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$66.00 ➝ $77.00Low
i
1/2/2019CitigroupUpgradeNeutral ➝ Buy$69.00 ➝ $76.00Low
i
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$77.00Medium
i
12/4/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$72.00 ➝ $76.00High
i
11/27/2018UBS GroupInitiated CoverageBuy$80.00High
i
11/13/2018CitigroupLower Price TargetNeutral ➝ Neutral$76.00 ➝ $69.00Medium
i
11/8/2018Royal Bank of CanadaLower Price TargetPositive ➝ Sector Perform$76.00 ➝ $70.00N/A
i
11/5/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$75.00 ➝ $66.00Low
i
11/2/2018ArgusUpgradeHold ➝ Buy$70.00Low
i
11/1/2018Piper Jaffray CompaniesLower Price TargetOverweight$83.00 ➝ $72.00Low
i
11/1/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$86.00 ➝ $76.00Medium
i
11/1/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$90.00 ➝ $77.00Medium
i
11/1/2018Raymond JamesLower Price TargetOutperform ➝ Outperform$80.00 ➝ $74.00Low
i
11/1/2018Wells Fargo & CompanyLower Price TargetOutperform ➝ Outperform$82.00 ➝ $72.00Medium
i
10/15/2018BarclaysInitiated CoverageUnderweight ➝ Underweight$73.00Medium
i
10/11/2018Morgan StanleyBoost Price TargetUnderweight$68.00 ➝ $75.00Low
i
9/4/2018ArgusReiterated RatingHoldLow
i
7/31/2018CitigroupBoost Price TargetNeutral ➝ Neutral$74.00 ➝ $76.00Medium
i
7/27/2018Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$77.00 ➝ $83.00Medium
i
7/27/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$80.00 ➝ $85.00High
i
7/27/2018Royal Bank of CanadaReiterated RatingHold$76.00High
i
5/31/2018Piper Jaffray CompaniesReiterated RatingOverweight$77.00Medium
i
5/22/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$73.00 ➝ $83.00Low
i
5/17/2018Piper Jaffray CompaniesInitiated CoverageOverweight$77.00Low
i
4/30/2018CitigroupBoost Price TargetNeutral ➝ Neutral$70.00 ➝ $72.00Medium
i
4/30/2018Stifel NicolausBoost Price TargetHold ➝ Hold$71.00 ➝ $72.00Medium
i
2/20/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$80.00Low
i
2/6/2018CitigroupBoost Price TargetNeutral ➝ Neutral$66.00 ➝ $70.00Medium
i
2/2/2018Royal Bank of CanadaReiterated RatingHold$72.00Medium
i
2/2/2018BarclaysBoost Price TargetOverweight ➝ Overweight$73.00 ➝ $77.00Medium
i
2/2/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$74.00 ➝ $77.00Medium
i
1/3/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$73.00Medium
i
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$71.00Medium
i
1/2/2018Bank of AmericaUpgradeNeutral ➝ BuyHigh
i
1/2/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
i
11/22/2017Bank of AmericaReiterated RatingHoldN/A
i
11/22/2017Royal Bank of CanadaReiterated RatingHold$66.00N/A
i
10/26/2017Stifel NicolausReiterated RatingHold$65.00N/A
i
10/26/2017BarclaysBoost Price TargetOverweight$70.00 ➝ $73.00N/A
i
10/26/2017Morgan StanleyBoost Price TargetEqual Weight$59.00 ➝ $62.00N/A
i
10/15/2017CowenSet Price TargetHold$68.00N/A
i
Rating by Josh Jennings at Cowen Inc
10/13/2017CowenReiterated RatingHold ➝ NeutralN/A
i
10/13/2017BMO Capital MarketsReiterated RatingBuy$70.00N/A
i
10/3/2017Royal Bank of CanadaReiterated RatingHold$60.00Low
i
9/1/2017Royal Bank of CanadaReiterated RatingHold$60.00N/A
i
8/17/2017CitigroupInitiated CoverageNeutral ➝ Neutral$63.00Low
i
7/28/2017UBS GroupBoost Price TargetNeutral$57.00 ➝ $62.00Low
i
7/27/2017SVB LeerinkReiterated RatingOutperform$67.00 ➝ $75.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
7/27/2017CowenReiterated RatingMarket Perform$66.00 ➝ $68.00Low
i
7/27/2017BarclaysBoost Price TargetOverweight$64.00 ➝ $70.00Low
i
7/26/2017Cantor FitzgeraldSet Price TargetBuy$70.00Medium
i
Rating by Travis Steed at Cantor Fitzgerald
7/25/2017Morgan StanleyReiterated RatingUnderweight$52.00 ➝ $55.00Medium
i
7/11/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$55.00 ➝ $70.00Low
i
7/10/2017CowenReiterated RatingMarket Perform$57.00 ➝ $66.00Low
i
6/29/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$70.00Low
i
6/14/2017BarclaysBoost Price TargetOverweight$62.00 ➝ $64.00Low
i
5/31/2017Stifel NicolausBoost Price TargetHold$58.00 ➝ $61.00Low
i
5/16/2017Goldman Sachs GroupReiterated RatingConviction-Buy$71.00High
i
5/1/2017CowenBoost Price TargetMarket Perform$48.00 ➝ $57.00Low
i
4/29/2017Evercore ISIReiterated RatingOutperform$57.00 ➝ $60.00Low
i
4/28/2017Morgan StanleyBoost Price TargetUnderweight$48.00 ➝ $52.00Low
i
4/27/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$55.00 ➝ $58.00Low
i
4/27/2017BMO Capital MarketsReiterated RatingHold$55.00Low
i
4/17/2017Evercore ISIReiterated RatingOutperform$57.00Low
i
4/4/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$54.00 ➝ $64.00Medium
i
Rating by D. Antalffy at SVB Leerink LLC
2/2/2017UBS GroupBoost Price TargetNeutral$51.00 ➝ $52.00N/A
i
2/2/2017BarclaysReiterated RatingOverweight$57.00 ➝ $60.00N/A
i
2/1/2017Evercore ISIBoost Price TargetBuy$50.00 ➝ $51.50N/A
i
10/26/2016Royal Bank of CanadaReiterated RatingSector Perform$50.00 ➝ $55.00N/A
i
10/26/2016Evercore ISIReiterated RatingBuy$52.00 ➝ $56.00N/A
i
Rating by Vijay Kumar at Evercore ISI
10/26/2016Royal Bank of CanadaBoost Price TargetSector Perform$50.00 ➝ $55.00N/A
i
10/13/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
9/15/2016BarclaysInitiated CoverageOverweight$52.00N/A
i
8/15/2016ArgusReiterated RatingHoldN/A
i
Rating by David Toung at Argus
7/28/2016UBS GroupBoost Price TargetNeutral$48.00 ➝ $50.00N/A
i
Rating by Matt Miksic at UBS Group AG
7/27/2016JPMorgan Chase & Co.Boost Price TargetNeutral$45.00 ➝ $48.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
7/27/2016Royal Bank of CanadaReiterated RatingHold$47.00 ➝ $50.00N/A
i
7/27/2016Royal Bank of CanadaBoost Price TargetSector Perform$47.00 ➝ $50.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
7/8/2016JPMorgan Chase & Co.Reiterated RatingHold$45.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
7/6/2016Goldman Sachs GroupReiterated RatingBuyN/A
i
Rating by David Roman at Goldman Sachs Group Inc
6/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$60.00N/A
i
Rating by Brooks West at Piper Jaffray Companies
6/6/2016JPMorgan Chase & Co.Reiterated RatingNeutral$45.00N/A
i
5/24/2016UBS GroupReiterated RatingHoldN/A
i
Rating by Matt Miksic at UBS Group AG
5/17/2016SVB LeerinkUpgradeMarket Perform ➝ OutperformN/A
i
Rating by D. Antalffy at SVB Leerink LLC
5/10/2016Credit Suisse GroupReiterated RatingHoldN/A
i
Rating by Matthew Keeler at Credit Suisse Group AG
5/10/2016UBS GroupReiterated RatingHoldN/A
i
Rating by Matt Miksic at UBS Group AG
5/10/2016BMO Capital MarketsReiterated RatingHold$43.00N/A
i
Rating by Joanne Wuensch at BMO Capital Markets
5/10/2016Piper Jaffray CompaniesReiterated RatingOverweight$58.00 ➝ $60.00N/A
i
Rating by Brooks West at Piper Jaffray Companies
5/8/2016Morgan StanleyReiterated RatingSellN/A
i
Rating by David Lewis at Morgan Stanley
5/4/2016Evercore ISIInitiated CoverageBuy$51.00N/A
i
4/27/2016Royal Bank of CanadaReiterated RatingSector Perform$40.00 ➝ $47.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
4/25/2016Credit Suisse GroupBoost Price TargetNeutral$39.00 ➝ $45.00N/A
i
4/14/2016Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$39.00 ➝ $58.00N/A
i
3/24/2016ArgusReiterated RatingHoldN/A
i
3/21/2016SVB LeerinkUpgradeMarket Perform ➝ OutperformN/A
i
Rating by D. Antalffy at SVB Leerink LLC
2/3/2016BMO Capital MarketsBoost Price TargetMarket Perform$33.00 ➝ $38.00N/A
i
2/3/2016Goldman Sachs GroupBoost Price TargetBuy$45.00 ➝ $46.00N/A
i
2/3/2016Royal Bank of CanadaReiterated RatingHold$37.00 ➝ $40.00N/A
i
11/16/2015Piper Jaffray CompaniesLower Price TargetOverweight ➝ Overweight$90.00 ➝ $39.00N/A
i
11/13/2015Goldman Sachs GroupBoost Price Target$43.00N/A
i
10/28/2015SVB LeerinkReiterated RatingMarket Perform$42.00N/A
i
10/28/2015CowenLower Price Target$74.00 ➝ $38.00N/A
i
(Data available from 10/27/2015 forward)
Baxter International logo
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Read More

Today's Range

Now: $80.01
$79.53
$80.93

50 Day Range

MA: $80.80
$78.33
$83.19

52 Week Range

Now: $80.01
$69.10
$95.19

Volume

2,375,665 shs

Average Volume

2,470,949 shs

Market Capitalization

$40.50 billion

P/E Ratio

24.17

Dividend Yield

1.21%

Beta

0.77